BMS-986251
| Code | Size | Price |
|---|
| TAR-T40123-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
BMS-986251 is an orally active and selective RORγt inverse agonist with an EC 50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC 50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis).
CAS:
2460133-35-9
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Robert J. Cherney, et al. Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist. ACS Med. Chem. Lett. 2020, 11, 6, 1221?1227